COVID-19 vaccine-induced myocarditis: Case report with literature review.

[1]  G. Cicero,et al.  Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction? , 2021, Canadian Journal of Cardiology.

[2]  A. Roguin,et al.  Myocarditis following COVID-19 mRNA vaccination , 2021, Vaccine.

[3]  G. Aurigemma,et al.  Myocarditis following COVID-19 vaccination , 2021, Radiology Case Reports.

[4]  Aridane Cárdenes León,et al.  Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19 , 2021, Revista Española de Cardiología (English Edition).

[5]  C. Giannattasio,et al.  Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection , 2021, IJC Heart & Vasculature.

[6]  G. Finocchiaro,et al.  COVID-19 and myocarditis: a systematic review and overview of current challenges , 2021, Heart Failure Reviews.

[7]  I. Douglas,et al.  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.

[8]  D. Mele,et al.  Myocarditis in COVID-19 patients: current problems , 2021, Internal and Emergency Medicine.

[9]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[10]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[11]  K. Sawalha,et al.  Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome , 2020, Cardiovascular Revascularization Medicine.

[12]  Zeyu Chen,et al.  T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.

[13]  Zhenghao Xu,et al.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies , 2020, Frontiers in Immunology.

[14]  M. Salifu,et al.  A Systematic Review of COVID-19 and Myocarditis , 2020, American journal of medical case reports.

[15]  L. Cooper,et al.  Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management , 2020, Heart Rhythm.

[16]  Guiqiang Wang,et al.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality , 2020, International Journal of Antimicrobial Agents.

[17]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[18]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[19]  L. Cooper,et al.  Recognition and Initial Management of Fulminant Myocarditis , 2020, Circulation.

[20]  J. Krejčí,et al.  Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment , 2016, BioMed research international.

[21]  R. Obst.  The Timing of T Cell Priming and Cycling , 2015, Front. Immunol..

[22]  G. Anderson,et al.  Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release , 2015, Immunity.

[23]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[24]  S. Heymans,et al.  Acute viral myocarditis , 2008, European heart journal.

[25]  B. McManus,et al.  Molecular biology and pathogenesis of viral myocarditis. , 2008, Annual review of pathology.

[26]  S. Iliceto,et al.  Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy , 2008, Autoimmunity.

[27]  C. Kramer,et al.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial In fl ammation Expert Recommendations , 2018 .

[28]  William Bracamonte-Baran,et al.  Cardiac Autoimmunity: Myocarditis. , 2017, Advances in experimental medicine and biology.